Vitiligo, New Treatment and Serum s100B
Serum s100B in Generalized Vitiligo and Its Relation to Oral Baricitinib, Narrow Band Ultraviolet (B) Therapy
South Valley University
50 participants
Oct 2, 2024
INTERVENTIONAL
Conditions
Summary
vitiligo is an autoimmune depigmenting skin disorder characterized by milky white macules or patches, with 2% worldwide prevalence. Vitiligo has unexpected course that significantly influences on patient's quality of life and self-esteem. Multiple medications have been introduced for vitiligo treatment, in this study we work on one of systemic JAK inhibitors
Eligibility
Inclusion Criteria2
- active generalized vitiligo patients with body surface area involved >5% excluding hands and feet
- no systemic treatment for vitiligo for the last 3 months or topical treatment received for the last 4 weeks.
Exclusion Criteria6
- acrofacial, acral, segmental or mucosal vitiligo
- patients on another immunosuppressive agent
- patients have other skin conditions (psoriasis, SLE, alopecia areata) that would interfere with evaluations of the effect of study medication on vitiligo.
- patients who suffered from systemic diseases affecting S100B (e.g. Subarachnoid hemorrhage, Alzheimer disease and inflammatory diseases) or from other dermatological diseases affecting S100B level (e.g. malignant melanoma)
- Patients immunocompromised, uncontrolled arterial hypertension, clinically serious viral, bacterial, fungal, or parasitic infection, anemia, history of thromboembolic event, cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, lymphoproliferative disease, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness.
- Pregnancy and lactation.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
oral baricitinib 4mg for adults and 2mg for children 10-16 years for group A
pulse dose of oral dexamethasone 2.5mg for adults for two consecutive days per week and half the dose for children
narrowband ultraviolet rays B phototherapy two sessions per week
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06768840